Next Steps and they are NOT obvious
Every once in a while a drug comes along that seems to have blockbuster written all over it. In the case of tirzepatide from Lilly we’d even go as far as mega-blockbuster. To say that tirzepatide is widely anticipated is like saying people are looking forward to summer.
Now that the drug has completed its extensive clinical program and is set to be submitted to the FDA a complex set of choices faces not just Lilly but also Novo Nordisk who must deal with the impact of this new widely anticipated drug which we should be easily approved . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.